scholarly journals Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular carcinoma: a meta-analysis

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Shan Tang ◽  
Jing Zhang ◽  
Ting-Ting Mei ◽  
Hai-Qing Guo ◽  
Xin-Huan Wei ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Gene Polymorphism ◽  
Meta Analysis ◽  
Case Control Studies ◽  
Exclusion Criteria ◽  
The Relationship ◽  
Significant Publication Bias ◽  
Allele Contrast ◽  
Common Malignancy

Abstract Background Hepatocellular carcinoma (HCC) is the sixth-most common malignancy worldwide. Multiple previous studies have assessed the relationship between TM6SF2 gene polymorphism and the risk of developing HCC, with discrepant conclusions reached. To assess the association of TM6SF2 rs58542926 T/C gene polymorphism with liver cancer, we performed the current meta-analysis. Methods This study queried the MEDLINE, PubMed, EMBASE, and CENTRAL databases from inception to April 2019. Case-control studies assessing the relationship between TM6SF2 rs5854292 locus polymorphism and liver cancer were selected according to inclusion and exclusion criteria. The Stata 12.0 software was employed for data analysis. Results A total of 5 articles, encompassing 6873 patients, met inclusion criteria and were included in the meta-analysis. Statistical analysis showed that the TM6SF2 gene polymorphism was significantly associated with liver cancer in the allele contrast, dominant, recessive and over dominant models (T vs C, OR = 1.621, 95%CI 1.379–1.905; CT + TT vs CC. OR = 1.541, 95%CI 1.351–1.758; TT vs CT + CC, OR = 2.897, 95%CI 1.690–4.966; CC + TT vs TC, OR = 0.693, 95%CI 0.576–0.834). The Egger’s test revealed no significant publication bias. Conclusion The present findings suggest a significant association of TM6SF2 gene polymorphism with HCC risk in the entire population studied.

scholarly journals Association between TM6SF2 rs58542926 T/C gene polymorphism and significant liver fibrosis: A meta-analysis

2020 ◽  
Author(s):  
Ting-Ting Mei ◽  
Jing Zhang ◽  
Shan Tang ◽  
Hai-Qing Guo ◽  
Xin-Huan Wei ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Gene Polymorphism ◽  
Hepatic Fibrosis ◽  
Meta Analysis ◽  
Case Control Studies ◽  
Exclusion Criteria ◽  
The Relationship ◽  
Significant Publication Bias ◽  
Allele Contrast ◽  
Significant Liver Fibrosis

AbstractAimTo further explore the association between Transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 T/C gene polymorphism and hepatic fibrosis.Materials and MethodsIn this study the MEDLINE, PubMed, EMBASE, and CENTRAL databases were queried from inception to March 21, 2020. According to inclusion and exclusion criteria, case-control studies assessing the relationship between TM6SF2 rs58542926 T/C gene polymorphism and significant liver fibrosis were selected. NOS scale was used to evaluate the included literature. Stata 12.0 software was used for data analysis.ResultsIn this meta-analysis,a total of 7 articles, including 2286 patients were included. Statistical analysis showed that the TM6SF2 gene polymorphism was associated with significant liver fibrosis in the allele contrast, recessive dominant models (T vs. C, OR=1.292, 95%CI 1.035-1.611, P=0.023; TT vs. CT+CC, OR=2.829, 95%CI 1.101-7.267, P=0.031). No significant publication bias was found after Egger’s test.ConclusionThe present findings suggest that the TT genotype and T gene of TM6SF2 rs58542926 T/C gene polymorphism are associated with susceptibility to significant hepatic fibrosis.

scholarly journals Association between the Interleukin-10 -1082 G/A polymorphism and risk of hepatocellular carcinoma

2020 ◽  
Vol 20 (1) ◽  
pp. 351-358
Author(s):  
Yingwei Wang ◽  
Peiyang Hu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Meta Analysis ◽  
Group Analysis ◽  
Interleukin 10 ◽  
Recessive Model ◽  
Case Control Studies ◽  
Exclusion Criteria ◽  
Keywords Hepatocellular Carcinoma ◽  
Relationship Of ◽  
The Relationship

Background: Inconsistent results have been reported from studies investigating the relationship of the interleukin-10 (IL-10) -1082 G/A polymorphism and the susceptibility of hepatocellular carcinoma (HCC). Therefore, a thorough literature review of relatedstudies was performed in this meta-analysis to examine the association of the interleukin-10(IL-10) -1082 G/A poly- morphism with HCC susceptibility. Methods: Electronic databases were searched for literature on the relationship between interleukin-10(IL-10) -1082 G/A poly- morphism and the risk of HCC in accordance with the inclusion and exclusion criteria. The selected studies were analyzed using the Stata 12.0 software. Finally, the strength of the associations was evaluated using the odds ratio (OR) and 95% confidence intervals (95% CI). Results: A total of six case-control studies were enrolled into the current meta-analysis, which included a total of 911 patients and 1889 control subjects. Our data revealed no association between the IL-10 -1082 G/A polymorphism and the risk of HCC (GG vs AA:OR=0.84, 95%CI=0.57-1.25; AG vs AA:OR=0.85, 95%CI=0.70-1.05; Dominant model: OR=0.85, 95%CI=0.70- 1.03; and Recessive model: OR=0.92, 95%CI = 0.64-1.32). Similarly, no association was found in sub-group analysis based on ethnicity. Conclusion: The results of our study suggest no association between IL-10 -1082 G/A polymorphism and the risk of HCC. Keywords: Hepatocellular carcinoma; IL-10 polymorphism; risk analysis. 

scholarly journals Association of ABO Polymorphisms and Pancreatic Cancer/ Cardiocerebrovascular Disease: a Meta-analysis.

2020 ◽  
Author(s):  
Yanxia Li ◽  
Luyang Liu ◽  
Yubei Huang ◽  
Hong Zheng ◽  
Lian Li
Keyword(s):  
Web Of Science ◽  
Meta Analysis ◽  
Case Control ◽  
Case Control Studies ◽  
Exclusion Criteria ◽  
Bias Assessment ◽  
Heterogeneity Test ◽  
Pancreatic Cancers ◽  
The Relationship ◽  
Eligible Case

Abstract Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular disease s. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/ cardiocerebrovascular disease s. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results : A total of nineteen articles involving twenty-two case-control populations were included according to inclusion and exclusion criteria. Twelve populations (20,820 cases and 27,837 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95%CI=1.05-1.22, P =0.001), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P <0.001). Five populations (8,660 cases and 10,618 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.18, 95%CI=1.13-1.23, P <0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P <0.001). Conclusion: Our study suggested that ABO polymorphisms might serve as a risk factor of pancreatic cancers and cardiocerebrovascular diseases.

scholarly journals Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs: a meta-analysis

2018 ◽  
Vol 33 (4) ◽  
pp. 364-371 ◽  
Author(s):  
Fei Lv ◽  
Yanju Ma ◽  
Ye Zhang ◽  
Zhi Li
Keyword(s):  
Gene Polymorphism ◽  
Odds Ratio ◽  
Adverse Reactions ◽  
Genetic Model ◽  
Meta Analysis ◽  
Case Control ◽  
Case Control Studies ◽  
Dominant Genetic Model ◽  
Positive Report ◽  
The Relationship

Although many previous studies have reported the relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs, the conclusions are not consistent. The aim of the study is to evaluate the association between granulocytopenia and thrombocytopenia induced by platinum-based drugs and GSTP1 rs1695 gene polymorphism by meta-analysis. A literature search was performed using the Pubmed, Embase, CNKI, and Wanfang databases, and the odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the correlation. Finally,12 case-control studies comprising 1657 patients were included in our study. GSTP1 rs1695 gene polymorphism showed a significant correlation with granulocytopenia induced by platinum-based drugs (dominant genetic model: OR=1.60, 95% CI=1.19. 2.15, P=0.002; recessive genetic model: OR=3.72, 95% CI=1.73, 8.00, P=0.001; allelic genetic model: OR=1.76, 95% CI=1.34, 2.33, P=0.001). This gene polymorphism is not associated with thrombocytopenia (OR=0.87, 95% CI=0.47, 1.60, P=0.649). False-positive report probability showed that the association between polymorphism and adverse reactions is true. Sensitivity analysis showed that the results were stable. However, there was a certain publication bias in the included studies. In conclusion, the GSTP1 rs1695 gene polymorphism is associated with granulocytopenia induced by platinum-based drugs.

scholarly journals Methylenetetrahydrofolate reductase C677T (Ala>Val, rs1801133 C>T) polymorphism decreases the susceptibility of hepatocellular carcinoma: a meta-analysis involving 12,628 subjects

2020 ◽  
Vol 40 (2) ◽  
Author(s):  
Sheng Zhang ◽  
Jiakai Jiang ◽  
Weifeng Tang ◽  
Longgen Liu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Methylenetetrahydrofolate Reductase ◽  
Meta Analysis ◽  
Case Control ◽  
Recessive Model ◽  
Case Control Studies ◽  
Independent Case ◽  
Synonymous Variant ◽  
Relationship Of ◽  
The Relationship

Abstract C677T (Ala&gt;Val, rs1801133 C&gt;T), a non-synonymous variant of methylenetetrahydrofolate reductase (MTHFR) gene, has been found to be associated with an impair enzyme activity of MTHFR. The relationship of MTHFR rs1801133 with hepatocellular carcinoma (HCC) has been extensively investigated. However, the findings were conflicting. Recently, more investigations have been conducted on the relationship of MTHFR rs1801133 with HCC. To obtain a more precise assessment on the effect of this non-synonymous variant to the development of HCC, a pooled-analysis was performed. This meta-analysis consisted of 19 independent case–control studies. By using the odds ratio (OR) combined with 95% confidence interval (CI), the relationship of MTHFR rs1801133 with HCC risk was determined. A total of 19 independent case–control studies were included. Finally, 6,102 HCC cases and 6,526 controls were recruited to examine the relationship of MTHFR rs1801133 with HCC risk. In recessive model (TT vs. CC/CT), the findings reached statistical significance (OR, 0.90; 95%CI, 0.82–0.98; P = 0.016). Subgroup analysis also found an association between MTHFR rs1801133 polymorphism and the decreased risk of HCC in hepatitis/virus related patients (recessive model: OR, 0.85; 95%CI, 0.72–0.99; P = 0.035, and allele model: OR, 0.90; 95%CI, 0.81–0.99; P = 0.028). Subgroup analyses indicated that extreme heterogeneity existed in Asian population, larger sample size investigation, hospital-based study and normal/healthy control subgroups. The shape of Begger’s seemed symmetrical. Egger’s linear regression test also confirmed these evaluations. Sensitivity analyses suggested that our findings were stable. In summary, our results highlight that MTHFR rs1801133 polymorphism decreases HCC susceptibility. The relationship warrants a further assessment.

scholarly journals Association of ABO Polymorphisms and Cancer/Cardiocerebrovascular Disease: a Meta-analysis

2019 ◽  
Author(s):  
Yanxia Li ◽  
Luyang Liu ◽  
Yubei Huang ◽  
Hong Zheng ◽  
Lian Li
Keyword(s):  
Gene Polymorphisms ◽  
Web Of Science ◽  
Meta Analysis ◽  
Case Control ◽  
Case Control Studies ◽  
Exclusion Criteria ◽  
Bias Assessment ◽  
Heterogeneity Test ◽  
The Relationship ◽  
Eligible Case

Abstract Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular diseases. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/cardiocerebrovascular diseases. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results: A total of eighteen articles involving twenty-nine case-control populations were included according to inclusion and exclusion criteria. Eleven populations (16,929 cases and 23,941 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95% CI=1.04-1.22, P=0.003), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P<0.001). Four populations (5,158 cases and 7,021 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.16, 95%CI=1.09-1.24, P<0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P<0.001). Conclusion: Our study suggested that ABO polymorphisms may serve as a risk factor of cancers and cardiocerebrovascular diseases.

scholarly journals Association between dopamine receptor D2 genetic polymorphism TaqIA1 (C t) and susceptibility to alcohol dependence

2020 ◽  
Author(s):  
Amrita Choudhary ◽  
Upendra Yadav ◽  
Pradeep Kumar ◽  
Vandana Rai
Keyword(s):  
Alcohol Dependence ◽  
Dopamine Receptor ◽  
Meta Analysis ◽  
Asian Population ◽  
Recessive Model ◽  
Case Control Studies ◽  
Drd2 Gene ◽  
Contrast Model ◽  
The Relationship ◽  
Allele Contrast

AbstractSeveral studies are published, which investigated dopamine receptor 2 (DRD2) gene TaqIA polymorphism as ris factor for alcohol dependence (AD) with positive and negative association. To derive a more precise estimation of the relationship, a meta-analysis of case-control studies that examined the association between DRD2 gene Taq1A polymorphism and alcohol dependence were performed. Eligible articles were identified through search of databases including PubMed, Science Direct, Springer link and Google Scholar. The association between the DRD2 TaqIA polymorphism and AD susceptibility was conducted using odds ratios (ORs) and 95 % confidence intervals (95 % CIs) as association measure.A total of 69 studies with 9,125 cases and 9,123 healthy controls were included in current meta-analysis. Results of present analysis showed significant association between DRD2 TaqIA polymorphism and AD risk using a five genetic modes (allele contrast model -OR=1.22, 95% CI=1.13-1.32, p<0.0001; homozygote model -OR= 1.35, 95%CI= 1.18-1.55; p= <0.0001; dominant model -OR= 1.29; 95%CI= 1.20-1.39; p<0.0001; recessive model-OR= 1.21; 95%CI= 1.08-1.36; p= 0.0006). There was no significant association found between In subgroup analysis, TaqIA polymorphism was not significantly associated with AD risk in Asian population under all genetic models, but in Caucasian population TaqIA polymorphism was significantly associated with AD risk.Overall, results support the hypothesis that DRD2 Taq1A polymorphism plays a role in alcohol dependence.

scholarly journals Association of ABO Polymorphisms and Pancreatic Cancer/ Cardiocerebrovascular Disease: a Meta-analysis.

2020 ◽  
Author(s):  
Yanxia Li ◽  
Luyang Liu ◽  
Yubei Huang ◽  
Hong Zheng ◽  
Lian Li
Keyword(s):  
Web Of Science ◽  
Meta Analysis ◽  
Case Control ◽  
Case Control Studies ◽  
Exclusion Criteria ◽  
Bias Assessment ◽  
Heterogeneity Test ◽  
Pancreatic Cancers ◽  
The Relationship ◽  
Eligible Case

Abstract Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular disease s. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/ cardiocerebrovascular disease s. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results : A total of nineteen articles involving twenty-two case-control populations were included according to inclusion and exclusion criteria. Twelve populations (20,820 cases and 27,837 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95%CI=1.05-1.22, P =0.001), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P <0.001). Five populations (8,660 cases and 10,618 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.18, 95%CI=1.13-1.23, P <0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P <0.001). Conclusion: Our study suggested that ABO polymorphisms might serve as a risk factor of pancreatic cancers and cardiocerebrovascular diseases.

scholarly journals Association of ABO Polymorphisms and Pancreatic Cancer/Cardiocerebrovascular Disease: a Meta-analysis

2020 ◽  
Author(s):  
Yanxia Li ◽  
Luyang Liu ◽  
Yubei Huang ◽  
Hong Zheng ◽  
Lian Li
Keyword(s):  
Web Of Science ◽  
Meta Analysis ◽  
Case Control ◽  
Case Control Studies ◽  
Exclusion Criteria ◽  
Bias Assessment ◽  
Heterogeneity Test ◽  
Pancreatic Cancers ◽  
The Relationship ◽  
Eligible Case

Abstract Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular disease s. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/ cardiocerebrovascular disease s. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results : A total of nineteen articles involving twenty-two case-control populations were included according to inclusion and exclusion criteria. Twelve populations (20,820 cases and 27,837 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95%CI=1.05-1.22, P =0.001), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P <0.001). Five populations (8,660 cases and 10,618 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.18, 95%CI=1.13-1.23, P <0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P <0.001). Conclusion: Our study suggested that ABO polymorphisms might serve as a risk factor of pancreatic cancers and cardiocerebrovascular diseases.

Sign in / Sign up

Export Citation Format

Share Document